ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

voclosporin

Also written as “LX211”, “Voclosporin” and “LUPKYNIS”.

Its studies are mostly in Lupus Nephritis · Psoriasis · Keratoconjunctivitis Sicca · Uveitis, Posterior · Glomerulosclerosis, Focal Segmental, led by 3 companies.

Drug pageVoclosporin: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 13, 202623 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurinia Pharmaceuticalsits history only171 open or runningphase 4since May 13, 2026Oct 25, 2005Mar 2, 2029phase 4 · NCT07611214
Lux Biosciences50 open or runningphase 3since Nov 27, 2006Nov 27, 2006none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 3since Mar 20, 2024Mar 20, 2024Jun 2027phase 3 · NCT06406205

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lux Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2006First studies: 3 phase 3 studiesFirst studyNCT00404885, NCT00404742, NCT00404612
  2. Feb 24, 2009Phase 1 study in Keratoconjunctivitis SiccaNCT00851734 · 35 enrolled · United States
  3. Nov 17, 2010Phase 3 study in Noninfectious UveitisNCT01243983 · 155 enrolled · United States, Austria, Brazil and more

TargetBeta

PPP3CA →read by rule
“Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor”ChEMBL 37, by rule

Studies

All 5 Lux Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01243983Noninfectious Uveitis · United States, Austria, Brazil and more3CompletedDec 2012155
NCT00851734Keratoconjunctivitis Sicca · United States1CompletedMar 200935
NCT00404885Uveitis, Anterior · United States, Austria, Canada and more3CompletedNov 2008108
NCT00404742Uveitis, Posterior · United States, Austria, Canada and more3CompletedNov 2008232
NCT00404612Uveitis, Posterior · United States, Austria, Canada and more3CompletedNov 2008218

How it is read

Names in the registry

  • “LX211”, 10 entries
  • “Voclosporin”, 7 entries
  • “voclosporin”, 6 entries
  • “LUPKYNIS”, 1 entry
  • “Voclosporin(QL1074)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.